## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 1.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($343.25)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Citi Cuts Stryker (SYK) PT, Maintains Buy Amid Leadership Changes**
- Source: Insider Monkey | 20251222T095300 | Somewhat-Bullish | Relevance: 100%
- Citi cut the price target for Stryker Corporation (NYSE: SYK) from $455 to $420, while maintaining a Buy rating, as part of a sector-wide adjustment for its 2026 outlook. The company also declared a quarterly dividend of $0.88 per share, a 4.8% increase, and appointed Spencer Stiles as President and COO, alongside other leadership changes. Stryker, a medical technology firm, utilizes AI in various healthcare applications, though the article suggests other AI stocks might offer greater returns.

**2. CCLA Investment Management Has $141.98 Million Position in Stryker Corporation $SYK**
- Source: MarketBeat | 20251222T100952 | Somewhat-Bullish | Relevance: 100%
- CCLA Investment Management has increased its stake in Stryker Corporation (NYSE:SYK) by 10.1%, now holding 384,158 shares valued at $141.98 million, making it their 18th largest holding. Despite significant insider selling over the past 90 days, institutional investors own 77.09% of the company. Stryker also reported strong quarterly earnings, beating estimates, and increased its quarterly dividend.

**3. Rep. Thomas H. Kean, Jr. Sells Stryker Corporation (NYSE:SYK) Stock**
- Source: MarketBeat | 20251220T071017 | Neutral | Relevance: 100%
- Representative Thomas H. Kean, Jr. recently sold shares of Stryker Corporation (NYSE:SYK) valued between $15,001 and $50,000. This comes as Stryker increased its quarterly dividend and reported an EPS beat, though significant insider selling has occurred recently. Analyst ratings for Stryker currently average a "Moderate Buy" with a consensus price target of $431.84.

**4. Does Becton Dickinsonâ€™s Recent Slide Create an Opportunity for Long Term Investors in 2025?**
- Source: Simply Wall Street | 20251222T202011 | Neutral | Relevance: 63%
- Becton Dickinson (NYSE: BDX) has seen its stock price decline, leading some to question if it presents a value opportunity. A Discounted Cash Flow (DCF) analysis suggests it is undervalued by 39.7%, with an estimated intrinsic value of $324.56 per share compared to its current price of $195.59. However, its Price-to-Earnings (PE) ratio of 33.2x is slightly above the industry average, indicating it is reasonably valued based on current earnings.

**5. 11 Best Healthcare AI Stocks to Buy Now**
- Source: Insider Monkey | 20251221T102300 | Neutral | Relevance: 59%
- This article highlights iRhythm Technologies, Inc. (NASDAQ: IRTC) as a top healthcare AI stock to consider. Morgan Stanley recently increased its price target for iRhythm Technologies, Inc. to $205, maintaining an Overweight rating due to a positive outlook for the MedTech industry. The company's Zio long-term continuous ECG monitoring system has also shown consistent performance across diverse patient populations.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Citizens | $440 | $0 | 0% |
| 2025-12-18 | Truist Securiti | $392 | $400 | -2% |
| 2025-12-11 | Citigroup | $420 | $455 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Citizens | up | Market Outperform |
| 2025-12-18 | Truist Securiti | main | Hold |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.76M) |
| Sells | 7 ($21.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $21M sold (7 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 23.9x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Analyst sentiment negative (2 target cuts vs 0 raises). Insider selling cluster ($21.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $136.3B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 23.9 |
| Current P/E | 26.3 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.1% (minimal 5-day change). Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 (-0.6%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 46. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.12% (CS: 54) | Neutral |
| RSI_14 | 45.6 | Neutral |
| MACD Histogram | -0.10 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 0.977x | Below |
| vs SMA200 | 0.950x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $356.45
- **Stop Loss:** $343.25 (3.7% risk)
- **Target:** $369.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $32,080.50
- **Portfolio %:** 32.08%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*